New Vision Medical Partners with Fujifilm Europe to Enter Major European Markets
Recently, New Vision Medical Technology (Suzhou) Co., Ltd. (hereinafter referred to as “New Vision Medical”) and Fujifilm Europe B.V., headquartered in the Netherlands (hereinafter referred to as “Fujifilm”),Jointly Announce Strategic Partnership Between the Two Companies.Under the agreement, Fujifilm, as the exclusive distributor, is responsible forXinguangwei Medical Disposable Electronic Bronchoscopein some major European countriessales and business development.
Data shows that,The global endoscopy market is a large and rapidly growing market.. According to data provided by Frost & Sullivan, driven by population aging, heightened health awareness, and continuous technological advancements, medical demand is steadily increasing. The global market size for medical endoscopes is projected to grow from USD 20.3 billion in 2020 at a compound annual growth rate (CAGR) of 6.9% to reach by 2030$39.6 billion. Driven by the growing need to mitigate the risks of cross-infection and hospital-acquired diseases, particularly in the context of the COVID-19 pandemic,The global market for single-use endoscopes is also growing rapidly.. According to data provided by Frost & Sullivan, the global market value of single-use medical endoscopes was USD 500 million in 2020 and is projected to increase to$9.2 billion.
Xinguangwei Medical's disposable electronic bronchoscope is a single-use flexible endoscope. By using this product, healthcare professionals are relieved of the need to disinfect used endoscopes after each procedure, thereby enablingConsecutive surgeries have improved surgical efficiency and reduced the overall costs for hospitals.This product also features various advanced technological characteristics, which canEnhancing the Surgical Experience for Physicians. The collaboration between Fujifilm and New Vision Medical hasTo enhance market acceptance of the product and boost its sales in Europe.
Xinguangwei Medical stated, “Disposable electronic endoscopes are one of the key research and development focuses of New Guangwei Medical in the field of medical endoscopy.. We believe that the strategic partnership with Fujifilm,This will secure us a greater competitive advantage over other brands and help us gradually increase our market share in overseas markets.We will seize this opportunity to enter the European market, fully leveraging our core technologies and product advantages. By utilizing Fujifilm’s extensive sales network and marketing resources in Europe, we will be able to effectively and efficiently demonstrate the performance and functional superiority of our products to overseas customers, with the expectation of achieving greater sales revenue from international markets. It is widely recognized that overseas sales serve as a litmus test for assessing the technological prowess of a medical device company.“This successful collaboration will undoubtedly serve as a strong testament to the innovation and high quality of New Vision Medical’s products.”
Phase I of the Global Headquarters and R&D Production Base of XinGuangWei Medical
As a global leader in healthcare and imaging, Fujifilm holds a leading position in the flexible endoscopy market, with its products enjoying a strong reputation worldwide. Fujifilm appreciates the opportunity to collaborate with Sinowei Medical, a promising player in the medical endoscopy industry.and believe that this collaboration will create significant value for both parties.Fujifilm will make every effort to promote Xinguangwei Medical’s products in Europe, aiming to provide safe, effective, and innovative endoscopic solutions for doctors and patients worldwide.
November 14–17, 2022 ((Local Time) New Vision Medical Partners with Innovative Endoscopy Solutions to Make a DebutMEDICA 2022Exhibition(Booth: H9 E63)As the world’s largest medical device exhibition, MEDICA will be held in Düsseldorf, Germany. For more information about MEDICA 2022, please follow New Optical Vision Medical’s official WeChat account. You are welcome to visit the New Optical Vision Medical booth!
New Vision Medical was established in October 2016 as a minimally invasive diagnosis and treatment company focused on the research, development, and commercialization of medical endoscopes and related innovative products. Adhering to the core strategic principle of “Based in China, with a Global Vision,” the company has established R&D centers in both China and Japan. Leveraging its robust independent R&D capabilities, New Vision Medical has built five core technology platforms and developed a comprehensive portfolio of marketed and pipeline medical endoscopy products. These solutions cover all types of endoscopic procedures performed across various clinical departments in hospitals, meeting the diverse needs of physicians and patients worldwide. Guided by its corporate values of “Clinical Focus,” “Collaborative Innovation,” “People-Centricity,” and “Excellence and Efficiency,” New Vision Medical is committed to continuously advancing minimally invasive diagnostic and therapeutic technologies. By enhancing market penetration through superior product performance, the company aims to become the preferred brand trusted by doctors and patients globally.
Fujifilm has more than 50 group companies and branches in Europe, with over 5,000 employees engaged in R&D, manufacturing, sales, and services. Fujifilm Europe GmbH, located in Ratingen, Germany, serves as the strategic headquarters for the region. Across Europe, Fujifilm provides solutions to a wide range of industries, including healthcare technology, biopharmaceuticals, electronic materials, industrial products, chemicals, graphic systems, optical devices, data storage, and all aspects of photography. Over the past two decades, the company has intensified its focus on the healthcare sector—spanning diagnosis, prevention, and treatment. Today, Fujifilm not only delivers comprehensive patient care solutions in Europe but also conducts research, development, and manufacturing in advanced therapies, gene therapies, and vaccines, while providing cell culture media and regenerative medicine solutions.